{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:40:54Z","timestamp":1777927254388,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>Raltegravir (RAL) is an HIV-1 integrase strand transfer inhibitor that is well established as a component of highly active antiretroviral therapy regimens for the treatment of adults living with human immunodeficiency virus (HIV), due to its high virological efficacy and good tolerability profile. To date, limited data are available on the use of RAL with abacavir\/lamivudine (ABC\/3TC). We investigated retrospectively 62 HIV-1 infected patients managed by three Italian Infectious Diseases Outpatient Departments, including 57 treatment-experienced patients and 5 treatment-na\u00efve patients, treated with ABC\/3TC plus RAL. In all five na\u00efve patients (100%), virological suppression was achieved and maintained , while 55 experienced patients (96.5%) maintained viral suppression at the most recent review. In the treatment-experienced patients, we observed a significant decrease in triglyceride levels (p\u2009&lt;\u20090.01), while liver transaminases, renal function and cholesterol levels remained substantially stable. In the 34 treatment-experienced patients who switched from a protease inhibitor (PI)-based regimen, we observed a significant improvement of total cholesterol (p=0.03) and triglyceride (p\u2009&lt;\u20090.01) levels. No significant alterations were found on renal and liver function and serum lipid profile of treatment-na\u00efve patients. Despite the small number of participants, results support the efficacy and safety of ABC\/3TC plus RAL, either in treatment-na\u00efve or treatment-experienced patients.<\/jats:p>","DOI":"10.1177\/0956462418817049","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T20:35:31Z","timestamp":1547152531000},"page":"467-471","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of abacavir\/lamivudine with raltegravir in treatment-experienced and treatment-na\u00efve patients with HIV-1 infection: an observational, retrospective, multi-centre study"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1104-1401","authenticated-orcid":false,"given":"Sebastiano","family":"Rizzardo","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Lanzafame","sequence":"additional","affiliation":[{"name":"\u201cDiagnosis and Therapy of HIV Infection\u201d Unit, G.B. Rossi University Hospital, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Lattuada","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Bragantini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Nicol\u00e8","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Calza","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Policlinico Sant\u2019Orsola-Malpighi, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelina","family":"Tacconelli","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"bibr1-0956462418817049","unstructured":"U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf (accessed 27 March 2018)."},{"key":"bibr2-0956462418817049","unstructured":"European AIDS Clinical Society Guidelines. Version 9.0, www.eacsociety.org\/files\/guidelines_9.0-english.pdf (2017, accessed 19 November 2018)."},{"key":"bibr3-0956462418817049","unstructured":"Societ\u00e0 Italiana di Malattie Infettive e Tropicali. Linee Guida Italiane sull\u2019utilizzo della Terapia Antiretrovirale e la gestione diagnostico-clinica delle persone con infezione da HIV-1 Edizione. www.simit.org\/medias\/1257-l-g-hiv-simit-2017.pdf (2017, accessed 19 November 2018)."},{"key":"bibr4-0956462418817049","unstructured":"FDA. Drug approval package: Isentress (raltegravir), www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022145_Isentress.cfm (2007, accessed 19 November 2018)."},{"key":"bibr5-0956462418817049","unstructured":"European Medicines Agency. Isentress (raltegravir), www.ema.europa.eu\/ema\/index.jspcurl=pages\/medicines\/human\/medicines\/000860\/human_med_000859.jsp&mi=WC0b01ac058001d124 (2008, accessed 19 November 2018)."},{"key":"bibr6-0956462418817049","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2014.236"},{"key":"bibr7-0956462418817049","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.66.317"},{"key":"bibr8-0956462418817049","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2017.1374552"},{"key":"bibr9-0956462418817049","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/00365548.2013.840920","volume":"46","author":"Fabbiani M","year":"2014","journal-title":"Scan J Infect Dis"},{"key":"bibr10-0956462418817049","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198768"},{"key":"bibr11-0956462418817049","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0150"},{"key":"bibr12-0956462418817049","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70257-3"},{"key":"bibr13-0956462418817049","doi-asserted-by":"publisher","DOI":"10.1310\/hct1105-260"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462418817049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0956462418817049","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462418817049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:39:04Z","timestamp":1777675144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0956462418817049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1177\/0956462418817049"],"URL":"https:\/\/doi.org\/10.1177\/0956462418817049","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,10]]}}}